ArticleCaspian journal of internal medicine2025
Relationship between serum irisin levels and renal function in patients with type 2 diabetes mellitus.
Article in Caspian journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irisin, a myokine implicated in metabolic hemostasis, have been investigated in relation to type 2 diabetes mellitus (T2DM), yet findings on its serum levels and association with diabetic complications such as nephropathy remain inconsistent. This study aimed to assess the relationship between serum irisin levels and renal function in T2DM patients. Methods: A cross-sectional study was conducted involving 140 individuals diagnosed with T2DM. Demographic, anthropometric, and clinical data were recorded. Fasting blood samples were collected to determine serum irisin levels using the ELISA method. Additional biochemical measurements included fasting blood glucose, creatinine, HDL, LDL, triglycerides, HbA1c, and urinary albumin. Correlations between irisin levels and these parameters were analyzed. Patients were divided into two groups based on glomerular filtration rate (GFR) and albumin-to-creatinine ratio (ACR) to assess associations between irisin levels and renal function. Results: No statistically significant difference in serum irisin levels was observed between patients with reduced renal function (GFR≤60) and those with GFR>60 (10.45±6.54 vs. 13.32±10.59 ng/ml, P=0.08). In stratified analysis by ACR, patients with nephropathy displayed a non-significantly lower irisin level than those without (11.70±8.18 vs. 13.38±11.51, P=0.33). Serum irisin showed no significant correlations with FBS (P=0.05), insulin (P=0.06), LDL (P=0.96), HDL (P=0.61), or BMI (P=0.42). Conclusion: Lower irisin levels in T2DM patients with reduced renal function or nephropathy may indicate a potential role for irisin in diabetic renal disease progression. Serum irisin could serve as a prognostic biomarker for diabetic nephropathy pending further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.